Chlorhexidine Inhibits L1 Cell Adhesion Molecule–Mediated Neurite Outgrowth in Vitro

Total Page:16

File Type:pdf, Size:1020Kb

Chlorhexidine Inhibits L1 Cell Adhesion Molecule–Mediated Neurite Outgrowth in Vitro nature publishing group Articles Basic Science Investigation Chlorhexidine inhibits L1 cell adhesion molecule–mediated neurite outgrowth in vitro Aaron M. Milstone1, Penny Bamford2, Susan W. Aucott1, Ningfeng Tang2, Kimberly R. White2 and Cynthia F. Bearer2 BACKGROUND: Chlorhexidine is a skin disinfectant that Trace amounts of chlorhexidine can be absorbed through reduces skin and mucous membrane bacterial colonization the skin after a single bath in adults and term neonates. and inhibits organism growth. Despite numerous studies In 1976, Case (5) showed that, in adults, chlorhexidine “is assessing chlorhexidine safety in term infants, residual con- absorbed through intact human skin to an extraordinarily cerns have limited its use in hospitalized neonates, especially small degree, if at all.” This report only detected chlorhexidine low-birth-weight preterm infants. The aim of this study was in feces of adults following a hand wash with 5% chlorhexidine to assess the potential neurotoxicity of chlorhexidine on the digluconate. No chlorhexidine was detected in blood, indicat- developing central nervous system using a well-established ing ­minimal absorption. In term neonates, given a 1 or 2% in vitro model of neurite outgrowth that includes laminin and chlorhexidine bath, chlorhexidine was detected in 4 out of 20 L1 cell adhesion molecule (L1) as neurite outgrowth–promot- neonates (range: 13.5–26.7 ng/ml) (6). However, the interval ing substrates. between the bath and blood sampling was not reported, nor is METHODS: Cerebellar granule neurons are plated on poly it known when the chlorhexidine concentration may peak in L-lysine, L1, or laminin. Chlorhexidine, hexachlorophene, or the blood after topical exposure. There are no reports of imme- their excipients are added to the media. Neurons are grown for diate adverse consequences as a result of chlorhexidine absorp- 24 h, fixed, and neurite length is measured. tion in studies of term newborns or adults, no data to suggest RESULTS: Chlorhexidine significantly reduced the length that detectable serum concentrations have clinical importance of neurites grown on L1 but not on laminin. Chlorhexidine (7), and no data that chlorhexidine can cross the blood–brain concentrations as low as 125 ng/ml statistically significantly barrier. Another broad-spectrum organopolychlorinated anti- reduced neurite length on L1. Hexachlorophene did not affect septic, hexachlorophene (HEX), was found to penetrate intact neurite length. human skin and cause vacuolar encephalopathy in newborns CONCLUSION: Chlorhexidine at concentrations detected in in the 1970s (8,9), thus showing that antiseptics used with- the blood following topical applications in preterm infants spe- out harm in adults can cause devastating neurological injury cifically inhibited L1-mediated neurite outgrowth of cerebellar in infants. As a result, chlorhexidine has been scrutinized for granule neurons. It is now vital to determine whether the blood– its potential to be absorbed through the skin. Despite numer- brain barrier is permeable to chlorhexidine in preterm infants. ous studies assessing short-term outcomes from the use of chlorhexidine in term infants, residual concerns have limited hlorhexidine is a skin disinfectant that reduces skin and its use in hospitalized neonates, especially in low-birth-weight Cmucous membrane bacterial colonization and inhibits preterm infants (10). No developmental neurotoxicity stud- organism growth. It is frequently used to prevent infections ies have been performed to assess the safety of chlorhexidine and the spread of antibiotic-resistant bacteria, such as meth- exposure in term or preterm neonates. icillin-resistant Staphylococcus aureus (1,2). Chlorhexidine Our goal is to begin studies on the impact of chlorhexidine is used to prepare the skin before surgical procedures and exposure on the developing central nervous system. In the reduces the risk of surgical site infections (3). The Centers current study, our objective was to assess the potential neu- for Disease Control and Prevention recommend cleaning rotoxicity of chlorhexidine using a well-established in vitro the skin with chlorhexidine before the placement of central model of neurite outgrowth (11,12) that includes both lam- venous catheters, because numerous studies have demon- inin and L1 cell adhesion molecule (L1) as outgrowth-pro- strated reduced catheter infection rates following chlorhexi- moting substrates. L1-mediated, but not laminin-mediated, dine skin preparation as compared with alternatives such neurite outgrowth is dependent on lipid rafts, portions of the as povidone–iodine. However, “no recommendation can be plasma membrane similar to bacterial membranes disrupted made for the safety or efficacy of chlorhexidine in infants by chlorhexidine (13). Thus, L1-mediated neurite outgrowth aged <2 mo” (4). may be a sensitive indicator of chlorhexidine neurotoxicity. 1Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland; 2Department of Pediatrics, University of Maryland School of Medicine, ­Baltimore, Maryland. Correspondence: Cynthia F. Bearer ([email protected]) Received 17 January 2013; accepted 29 May 2013; advance online publication 13 November 2013. doi:10.1038/pr.2013.175 8 Pediatric RESEArch Volume 75 | Number 1 | january 2014 Copyright © 2014 International Pediatric Research Foundation, Inc. Chlorhexidine inhibits neurite outgrowth Articles HEX has been shown to cause axonopathy in vitro. Although 2). Ethanol was used as a positive control for inhibition of chemically distinct, both chlorhexidine and HEX contain the L1-mediated neurite outgrowth. We chose the highest concen- lipophilic moieties of polychlorinated phenol rings, mak- tration of chlorhexidine detected in the serum of a newborn ing them both lipophilic. Measurement of neurite outgrowth following topical exposure (1,021 ng/ml) (15). As can be seen may be one way to demonstrate the potential neurotoxicity of in Figures 1 and 2, compared with L1 control, CHG reduced chlorhexidine and HEX (14). neurite length of CGNs plated on L1 (P < 0.05). The vehicle (V) Due to concerns that chlorhexidine may cause neurotoxic- in which CHG is solubilized had no effect on neurite length. ity to third-trimester equivalent preterm infants, cerebellar There was no apparent effect on neurite branching under any granule neurons (CGNs) are an ideal in vitro model, as neurite of these conditions. outgrowth of these neurons occurs at this age of development. To determine whether these reagents reduce cell viability, we Neurite outgrowth is a sensitive measure for nonlethal neuro- counted the number of cells per high-powered field. Nonviable toxicity and provides an excellent model to assess the potential cells lose adhesion and lift off the plates. Thus, decreasing cellular toxicity of chlorhexidine (11,12). Neurite outgrowth number of adherent cells would indicate increased cell death. occurs through different mechanisms depending on environ- There was no difference in the number of cells adherent to the mental cues. These cues include proteins either on the surface plate as compared with poly l-Lysine (PLL), and no difference of other cells or in the extracellular matrix. L1 is one such envi- was found between the number of cells adherent to the plate ronmental cue. It binds homophilically to itself, initiating the in V alone or V with CHG (Figure 3). processes of protein trafficking, phosphorylation/dephosphor- HEX is a known developmental neurotoxicant (8,9,16). The ylation, and signal transduction in the growth cone. Laminin ability of HEX to inhibit L1-mediated neurite outgrowth was promotes neurite outgrowth by binding to the integrin recep- tested. The concentration of HEX used was 100× that in the tor and hence represents a different mechanism by which neu- serum of a newborn with liver disease (4,350 ng/ml) (17). rite outgrowth is promoted. Together, these cell lines provide We found no significant effect of either dimethyl sulfoxide an opportunity to investigate the potential neurotoxicity of (DMSO) alone or DMSO with 1 mmol/l HEX on L1-mediated chlorhexidine. neurite outgrowth (Figure 4). To determine whether the inhibition of neurite outgrowth RESULTS by CHG is specific to L1 or is a general effect on neurite out- We first tested whether chlorhexidine gluconate ((CHG) in a growth, we plated CGNs on laminin. Laminin is another cell proprietary vehicle (V)) inhibited L1-mediated neurite out- adhesion molecule that binds to integrin receptors. As can growth by plating CGNs on a substrate of L1 (Figures 1 and be seen in Figure 5, neither the vehicles nor CHG or HEX ab 20 µm 20 µm cd 20 µm 20 µm Figure 1. Chlorhexidine inhibits L1-mediated neurite outgrowth. Cerebellar granule neurons are plated on either poly L-lysine (PLL) alone or PLL plus L1-Fc (L1), and then, ethanol (E, final concentration: 25 mmol/l), chlorhexidine vehicle (V, final concentration: 1%), or chlorhexidine in vehicle (CHG, final concentration: 1.0 µg/ml CHG, 1% vehicle) are added to the media. The cells are grown for 24 h, fixed, and immunostained. Representative photomicro- graphs are shown: (a) PLL alone; (b) L1; (c) L1 + V; and (d) L1 + V + CHG. Original magnification: ×20. Copyright © 2014 International Pediatric Research Foundation, Inc. Volume 75 | Number 1 | january 2014 Pediatric RESEArch 9 Articles Milstone et al. 80 80 † 70 * 70 60 60 m) µ m) µ 50 50 40 40 † ite length ( ‡ ite length ( ** 30 30 Mean neur 20 Mean neur 20 10 10 0 PLL L1
Recommended publications
  • National Center for Toxicological Research
    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
    [Show full text]
  • Phenol Health and Safety Guide
    C - z_ IPCS INTERNATIONAL._ PROGRAMME ON CHEMICAL SAFETY OD 341 Health and Safety Guide No. 88 .P5 94 Ph c.2 PHENOL HEALTH AND SAFETY GUIDE ' UNITED NATIONS INTERNATIONAL ENVffiONMENTPROG~E LABOUR ORGANISATION WORLD HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION, GENEVA 1994 1 I) 1\ ' ~Ii>cs Other HEALTH AND SAFETY GUIDES available: (continued on inside back cover) Acrolein (No . 67, 1992) Endrin (No. 60, 1991) Acrylamide (No. 45 , 1991) Epichlorohydrin (No. 8, 1987) Acrylonitrile (No. I, 1986) Ethylene oxide (No. 16, 1988) Aldicarb (No. 64, 1991) Fenitrothion (No. 65, 1991) Aldrin and dieldrin (No. 21 , 1988) Fenvalerate (No. 34, 1989) Allethrins (No. 24, 1989) Folpet (No. 72, 1992) Amitrole (No. 85 , 1994) Formaldehyde (No. 57, 1991) Ammonia (No. 37, 1990) Heptachlor (No. 14, 1988) Arsenic compounds, inorganic, other than Hexachlorobutadiene (No. 84, 1993) arsine (No. 70, 1992) Hexachlorocyclohexanes, alpha- and Atrazine (No. 47, 1990) beta- (No. 53, 1991) Barium (No. 46 , 1991) Hexachlorocyclopentadiene (No. 63 , 1991) Benomyl (No. 81, 1993) n-Hexane (No. 59, 1991) Bentazone (No. 48, 1990) Hydrazine (No. 56, 1991) Beryllium (No. 44, 1990) Isobenzan (No. 61 , 1991) !-Butanol (No. 3, 1987) Isobutanol (No. 9, 1987) 2-Butanol (No. 4, 1987) Kelevan (No. 2, 1987) ten-Butanol (No. 7, 1987) Lindane (No. 54 , 1991) Camphechlor (No. 40, 1990) Magnetic fields (No. 27, 1990) Captafol (No. 49, 1990) Methamidophos (No. 79, 1993) Captan (No. 50, 1990) Methyl bromide (Bromomethane) (No. 86, 1994) Carbaryl (No. 78, 1993) Methyl isobutyl ketone (No. 58, 1991) Carbendazim (No. 82, 1993) Methyl parathion (No. 75, 1992) Chlordane (No. 13 , 1988) Methylene chloride (No.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Chemical Matricectomy with Phenol Versus Aesthetic Reconstruction. a Single Blinded Randomized Clinical Trial
    Journal of Clinical Medicine Article The Treatment of Ingrown Nail: Chemical Matricectomy With Phenol Versus Aesthetic Reconstruction. A Single Blinded Randomized Clinical Trial Juan Manuel Muriel-Sánchez 1, Ricardo Becerro-de-Bengoa-Vallejo 2 , Pedro Montaño-Jiménez 1 and Manuel Coheña-Jiménez 1,* 1 Facultad de Enfermería, Fisioterapia y Podología, Universidad de Sevilla, 41009 Sevilla, Spain; [email protected] (J.M.M.-S.); [email protected] (P.M.-J.) 2 Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, 28040 Madrid, Spain; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 18 March 2020; Published: 20 March 2020 Abstract: Background: In onychocryptosis surgery, incisional and non-incisional matricectomy is indicated according to the stage. The chemical matricectomy with 88% phenol solution is the gold standard and a wedge resection is indicated for more advanced stages. The aesthetic reconstruction has the advantages of the incisional procedure without eponychium incisions and an effectiveness similar to the chemical matricectomy with phenol. Objective: To compare the recurrence and the healing time between the chemical matricectomy with phenol and the aesthetic reconstruction. Methods: A comparative, prospective, parallel, randomized, and one-blinded clinical trial was registered with the European Clinical Trials Database (EudraCT) with identification number 2019-001294-80. Thrity-four patients (56 feet) with 112 onychocryptosis were randomized in two groups. Thirty-six were treated with chemical matricectomy with phenol and 76 with aesthetic reconstruction. Each patient was blind to the surgical procedure assigned by the investigator. The primary outcome measurements were healing time and recurrence. The secondary outcome measurements were post-surgical bleeding, pain, inflammation, and infection rate.
    [Show full text]
  • Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité
    Avant-propos Le format de présentation de cette thèse correspond à une recommandation à la spécialité Maladies infectieuses, à l’intérieur du Master des Sciences de la Vie et de la Santé qui dépend de l’Ecole Doctorale des Sciences de la Vie de Marseille. Le candidat est amené à respecter les règles qui lui sont imposées et qui comportent un format de thèse utilisé dans le Nord de l’Europe et qui permet un meilleur rangement que les thèses traditionnelles. Par ailleurs, la partie introduction et bibliographie est remplacée par une revue envoyée dans un journal afin de permettre une évaluation extérieure de la qualité de la revue et de permettre à l’étudiant de commencer le plus tôt possible une bibliographie sur le domaine de cette thèse. Par ailleurs, la thèse est présentée sur article publié, accepté, ou soumis associé d’un bref commentaire donnant le sens général du travail. Cette forme de présentation a paru plus en adéquation avec les exigences de la compétition internationale et permet de se concentrer sur des travaux qui bénéficieront d’une diffusion internationale. Professeur Didier RAOULT 2 Remerciements J’adresse mes remerciements aux personnes qui ont contribué à la réalisation de ce travail. En premier lieu, au Professeur Didier RALOUT, qui m’a accueillie au sein de l’IHU Méditerranée Infection. Au Professeur Serge MORAND, au Docteur Marie KEMPF et au Professeur Philippe COLSON de m’avoir honorée en acceptant d’être rapporteurs et examinateurs de cette thèse. Je souhaite particulièrement remercier : Le Professeur Jean-Marc ROLAIN, de m’avoir accueillie dans son équipe et m’avoir orientée et soutenue tout au long de ces trois années de thèse.
    [Show full text]
  • Step-By-Step Guide to Better Laboratory Management Practices
    Step-by-Step Guide to Better Laboratory Management Practices Prepared by The Washington State Department of Ecology Hazardous Waste and Toxics Reduction Program Publication No. 97- 431 Revised January 2003 Printed on recycled paper For additional copies of this document, contact: Department of Ecology Publications Distribution Center PO Box 47600 Olympia, WA 98504-7600 (360) 407-7472 or 1 (800) 633-7585 or contact your regional office: Department of Ecology’s Regional Offices (425) 649-7000 (509) 575-2490 (509) 329-3400 (360) 407-6300 The Department of Ecology is an equal opportunity agency and does not discriminate on the basis of race, creed, color, disability, age, religion, national origin, sex, marital status, disabled veteran’s status, Vietnam Era veteran’s status or sexual orientation. If you have special accommodation needs, or require this document in an alternate format, contact the Hazardous Waste and Toxics Reduction Program at (360)407-6700 (voice) or 711 or (800) 833-6388 (TTY). Table of Contents Introduction ....................................................................................................................................iii Section 1 Laboratory Hazardous Waste Management ...........................................................1 Designating Dangerous Waste................................................................................................1 Counting Wastes .......................................................................................................................8 Treatment by Generator...........................................................................................................12
    [Show full text]
  • Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit
    Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Author(s): Caroline Quach, MD, MSc; Aaron M. Milstone, MD, MHS; Chantal Perpête, RN, LSH, LSHH; Mario Bonenfant, RN; Dorothy L. Moore, MD, PhD; Therese Perreault, MD Source: Infection Control and Hospital Epidemiology, Vol. 35, No. 2 (February 2014), pp. 158- 163 Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America Stable URL: http://www.jstor.org/stable/10.1086/674862 . Accessed: 24/01/2014 14:25 Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at . http://www.jstor.org/page/info/about/policies/terms.jsp . JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact [email protected]. The University of Chicago Press and The Society for Healthcare Epidemiology of America are collaborating with JSTOR to digitize, preserve and extend access to Infection Control and Hospital Epidemiology. http://www.jstor.org This content downloaded from 209.172.182.131 on Fri, 24 Jan 2014 14:25:10 PM All use subject to JSTOR Terms and Conditions infection control and hospital epidemiology february 2014, vol. 35, no. 2 original article Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Caroline Quach, MD, MSc;1,2,3 Aaron M.
    [Show full text]
  • Partial Nail Avulsion and Chemical Matricectomy: Ingrown Toenails
    Partial nail avulsion and chemical matricectomy: Ingrown toenails Intervention Removal (avulsion) of an ingrowing section of toenail and application of a caustic chemical to destroy the nail matrix (matricectomy). Indication Partial nail avulsion and chemical matricectomy relieve symptoms and prevent regrowth of the nail edge or recurrence of the ingrowing toenail. Possible causes of ingrowing toenails include improper Ingrowing toenails are a common problem and occur when the edge of the nail grows trimming of the nail, tearing nail into flesh at the side of the nail, causing a painful injury. The punctured skin can become off, overly curved nail, certain inflamed and infected. Ingrown toenails can be classified into three stages (see Figure 1): activities (eg running) and • mild (or Stage I) wearing constricting footwear. – oedema, erythema and pain • moderate (or Stage II) – inflammation and inflection with or without purulent discharge, in addition to the symptoms of Stage I • severe (or Stage III) – chronic inflammation, epithelialised hypertrophic granulation tissue. Figure 1. Three stages of ingrown toenails Source: Eekhof JA, Van Wijk B, Knuistingh Neven A, van der Wouden JC. Interventions for ingrowing toenails. The Cochrane Database of Systematic Reviews 2012;4:CD001541. Surgical interventions are commonly performed for patients in Stages II and III, and are more effective than non-surgical interventions in preventing the recurrence of an ingrowing toenail. The addition of chemical cauterisation (most commonly with phenol) at Stages II and III, may be more effective in preventing recurrence and regrowth of the ingrowing toenail than surgery alone. Contraindications Diminished vascular supply to the digit is a relative contraindication to nail surgery.
    [Show full text]
  • Hatchery Disinfection Policy and Procedures
    MAINE DEPARTMENT OF INLAND FISHERIES & WILDLIFE Chapter 11 Disinfection Policy & Procedures Editors: David C. Rayner, Fish Culture Supervisor, Governor Hill State Fish Hatchery, Augusta, Maine (19XX- Present) & G. Russell Danner MS, DVM, Fish Pathologist, Fish Health Laboratory, Augusta, Maine (1998 – Present) Date: September 24, 1999. “Or if a person touches anything ceremonially unclean-whether the carcasses of unclean wild animals or of unclean livestock or of unclean creatures that move along the ground-even though he is unaware of it, he has become unclean and is guilty” Lev. 5:2 Several factors should be included in an evaluation of a disinfectant. A prerequisite for a disinfectant is its effectiveness against the expected spectrum of pathogens (Table 11- 1, 11-2, and 11-3). A general guideline for effective killing of pathogens by a disinfectant is a 5-log killing of bacteria and a 4-log killing of viruses. In addition to the activity of the disinfectant, its compatibility with devices should be reviewed in detail; this should include a review of data on devices that have been immersed for longer than recommended times. Instruments can be forgotten after immersion, and this mistake should not necessarily result in irreparable damage to the device. Other issues are toxicity, odor, compatibility with other compounds, and residual activity. Various and numerous organisms can cause diseases in fish. Viruses, bacteria, fungi, protozoan and many invertebrate animals are included in this list. No single disinfectant destroys them all. It is up to the applicant to decide what is the pathogen of most concern, and how it is to be reduced or eliminated.
    [Show full text]
  • Phenol Red Solution, 1.0% Alcoholic MSDS # 523.00
    Material Safety Data Sheet Page 1 of 2 Phenol Red Solution, 1.0% Alcoholic MSDS # 523.00 Section 1: Product and Company Identification Phenol Red Solution, 1.0% Alcoholic Synonyms/General Names: N/A Product Use: For educational use only Manufacturer: Columbus Chemical Industries, Inc., Columbus, WI 53925. 24 Hour Emergency Information Telephone Numbers CHEMTREC (USA): 800-424-9300 CANUTEC (Canada): 613-424-6666 ScholAR Chemistry; 5100 W. Henrietta Rd, Rochester, NY 14586; (866) 260-0501; www.Scholarchemistry.com Section 2: Hazards Identification Red to orange color liquid, mild odor. HMIS (0 to 4) Health 1 WARNING! Alcohol based solution, flammable liquid and moderately toxic by ingestion. Fire Hazard 3 Flammable liquid, keep away from all ignition sources. Reactivity 0 Target organs: Central nervous system, liver, kidneys. This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200). Section 3: Composition / Information on Ingredients Phenol Red, sodium salt (3447-61-1), 1%. Isopropyl Alcohol (67-63-0), 49.5%. Water (7732-18-5), 49.5%. Section 4: First Aid Measures Always seek professional medical attention after first aid measures are provided. Eyes: Immediately flush eyes with excess water for 15 minutes, lifting lower and upper eyelids occasionally. Skin: Immediately flush skin with excess water for 15 minutes while removing contaminated clothing. Ingestion: Call Poison Control immediately. Aspiration hazard. Rinse mouth with cold water. Give victim 1-2 tbsp of activated charcoal mixed with 8 oz water. Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Section 5: Fire Fighting Measures Class IB Flammable Liquid.
    [Show full text]
  • Chemicals of High Concern List (Sorted Alphabetically), July 2010
    Minnesota Department of Health, Chemicals of High Concern list, July 1, 2010 Persistent, Bioaccumulative, Toxic or very CAS Persistent, very HPV (2006 and 3 of 4 Number Chemical Name Health endpoint(s) Bioaccumulative Source(s) Use example(s) or class years) (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2- Maine (EU Reproductive 5543-57-7 benzopyrone Reproduction Toxicant) Sunscreen Maine (CA Prop 65; IARC; EU Carcinogen; NTP 11th ROC; OSPAR Chemicals of High Concern); WA Appen1; 91-94-1 [1,1'-biphenyl]-4,4'-diamine, 3,3'-dichloro-Cancer x Minnesota HRL Dye, curing agent Maine (OSPAR Chemicals of [1,1'-biphenyl]-4,4'-diamine, N,N'-bis(2,4- Concern; Canada PBiT); WA 29398-96-7 dinitrophenyl)-3,3'-dimethoxy- x Appen1 Colorant [1,1'-Biphenyl]-4-ol, 3,4',5-tris(1,1- Maine (Canada PBiT); WA 6257-39-2 dimethylethyl)- x Appen1 [1,1'-Biphenyl]-4-ol, 3,4'-bis(1,1- Maine (Canada PBiT); WA 42479-88-9 dimethylethyl)- x Appen1 Chemical intermediate [1,1'-biphenyl]-4-ol, 3,5-bis(1,1- Maine (OSPAR Chemicals of 2668-47-5 dimethylethyl)- x Concern); WA Appen1 [2,6'-Bibenzothiazole]-7-sulfonic acid, 2'- (4-aminophenyl)-6-methyl-, diazotized, coupled with diazotized 4- aminobenzenesulfonic acid and Maine (Canada PBiT); WA 91696-90-1 resorcinol, sodium salts x Appen1 1(2H)-Quinolineethanol, 6-[(2-chloro-4,6- dinitrophenyl) azo]-3,4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63133-84-6 tetramethyl- x Appen1 1(2H)-Quinolinepropanamide, 6-(2,2- dicyanoethenyl)-3, 4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63467-15-2 tetramethyl-N-phenyl- x Appen1 1,1,1,2-Tetrachloro-2,2-bis(4-
    [Show full text]
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008
    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
    [Show full text]